SCHEMBL714202

SCHEMBL714202

C[C@H](Nc1ncnc(N)n1)c1cc2cccc(Cl)c2nc1N1CCN(C(=O)C2CC2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.42
PIK3CD O00329 3/20 0.41
PLA2G1B P04054 1/20 0.38
ATG4B Q9Y4P1 1/20 0.38
MTNR1B P49286 2/20 0.38
SOS1 Q07889 2/20 0.38
KIT P10721 1/20 0.38
LMNA P02545 1/20 0.37
POLB P06746 1/20 0.37
CNR1 P21554 1/20 0.37
CNR2 P34972 1/20 0.37
PIK3CA P42336 1/20 0.37
MTOR P42345 1/20 0.37
KRAS P01116 1/20 0.36
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
P2RX3 P56373 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL714203 1.00 MAPT (0.42) MAPTPIK3CDPLA2G1BATG4BMTNR1B
SCHEMBL15875835 0.92 PIK3CD (0.44) MAPTPIK3CDMTNR1BSOS1KIT
SCHEMBL15875832 0.92 PIK3CD (0.44) MAPTPIK3CDMTNR1BSOS1KIT
SCHEMBL715035 0.91 CNR2 (0.44) PIK3CDSOS1KITCNR1CNR2
SCHEMBL715036 0.91 CNR2 (0.44) PIK3CDSOS1KITCNR1CNR2
SCHEMBL715910 0.90 PIK3CD (0.40) PIK3CDKITLMNACNR1CNR2
SCHEMBL715911 0.90 PIK3CD (0.40) PIK3CDKITLMNACNR1CNR2
SCHEMBL715265 0.88 MAPT (0.42) MAPTPIK3CDMTNR1BSOS1LMNA
SCHEMBL715264 0.88 MAPT (0.42) MAPTPIK3CDMTNR1BSOS1LMNA
SCHEMBL715977 0.86 LRRK2 (0.44) PIK3CDSOS1CNR1CNR2PIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2403847-B1 TRIAZINE DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2016-03-02 EP claimed
US-8785628-B2 Triazine derivatives as kinase inhibitors UCB PHARMA, S.A. (BE) 2014-07-22 US claimed
EP-2403847-B1 TRIAZINE DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2016-03-02 EP disclosed
US-8785628-B2 Triazine derivatives as kinase inhibitors UCB PHARMA, S.A. (BE) 2014-07-22 US disclosed
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors UCB PHARMA, S.A. (BE) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors MAP3K15, PI4KA, MAP3K20 MAPT 1229/4885PIK3CD 12/4885PLA2G1B 1587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.